Chapter- 1: INTRODUCTION -- Complimentary
OBJECTIVES AND GOALS OF STUDY 1
INTENDED AUDIENCE 2
SCOPE OF REPORT 2
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 4
DISCLAIMER 4
Chapter-2: SUMMARY
SUMMARY (CONTINUED) 5
SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2007-2014 ($ MILLIONS) 6
Chapter-3: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY
TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET 7
TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR 8
HOW REGENERATIVE MEDICINE WORKS 8
TISSUES AND ORGANS ON DEMAND 9
ORGAN REPLACEMENT IS A $100 BILLION PER YEAR BUSINESS 10
EXAMPLES OF IMPACT ON EXISTING CONDITIONS AND DISEASES 10
BARRIERS TO REGENERATIVE MEDICINE 11
CURRENT R&D PRIORITIES 12
TABLE 2 PRINCIPAL REGENERATIVE MEDICINE BUSINESS R&D FOCUSES 13
TABLE 3 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS, 2015-2030 14
TOTAL OUTPUT OF THE SECTOR 15
REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS 15
POPULATION TRENDS 16
MARKET TIMING 16
OVERSEAS INITIATIVES 17
Chapter-4: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE
PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE 18
HUMAN SUBSTANCES 19
CELLS AND TISSUES 19
TISSUE ENGINEERING 19
Importance of Scaffolding in Tissue Engineering 20
Blood Vessel Scaffolding 21
Center for Integration of Medicine and Innovative Technology (CIMIT) 21
TABLE 4 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008–2010 22
Massachusetts General Hospital 22
Duke University Stem Cell and Regenerative Medicine Program 23
EMBRYONIC STEM CELLS 23
THERAPEUTIC CLONING 24
ADULT STEM CELLS: JUST AS GOOD AS EMBRYONIC STEM CELLS 24
GENZYME 24
UNIVERSITY OF MINNESOTA STEM CELL INSTITUTE 25
STEM CELL RESEARCH PATENTS AND EFFECT ON STEM CELL MARKETERS 26
SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS 26
NOVEL MATERIALS 27
GENE THERAPY 27
Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders 28
BIOREACTOR USE IN REGENERATIVE MEDICINE 29
TABLE 5 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE 29
THE IMPACT OF GENOMICS 30
Chapter-5: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE
GENE- AND PROTEIN-BASED APPROACHES 31
ANTIBODIES 31
The Importance of Antibody Drugs 32
Advantages of Monoclonal Antibody Drugs 33
Antibodies and Osteoarthritis 34
GROWTH FACTORS 35
GROWTH FACTORS (CONTINUED) 36
HOW BMPS FUNCTION 37
TABLE 6 BONE MORPHOGENETIC PROTEINS 38
Clinical Uses 38
Companies 39
CELLS AND TISSUES 40
TISSUE ENGINEERING 40
ARTIFICIAL SKIN 41
CARTILAGE 42
OTHER APPROACHES TO CARTILAGE 43
BIOSYNTHETIC COMPOSITES FOR CARTILAGE REPAIR 44
THE MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS 44
TABLE 7 U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2014 ($ MILLIONS) 45
OTHER PRODUCTS 45
CREATION OF ENTIRE ORGANS 45
CREATION OF ENTIRE ORGANS (CONTINUED) 46
EMBRYONIC STEM CELLS 47
NOVEL MATERIALS AND BIOMATERIALS 48
Chapter-6: STEM CELL THERAPIES AND REGENERATIVE MEDICINE
STEM CELLS AS POTENTIAL REPLACEMENT CELLS 49
TECHNICAL IMPEDIMENTS 50
OVERVIEW OF FUNDING 51
TABLE 8 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2008 ($ MILLIONS) 52
STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH 52
TABLE 9 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH 53
POTENTIAL APPLICATIONS: CURRENT STATUS 53
IN VIVO REPROGRAMMING 54
UMBILICAL CORD BLOOD STEM CELLS 55
Recent Research Developments 55
INDUCED PLURIPOTENT STEM CELLS 56
Recent Research Developments 56
Adult Multipotent Stem Cells 57
Embryonic Stem Cells 57
Embryonic Stem Cells (Continued) 58
GERON AND THE FIRST HUMAN TRIALS 59
GERON AND THE FIRST HUMAN TRIALS (CONTINUED) 60
OTHER STEM CELL RESEARCH 61
STATUS OF OTHER CLINICAL TRIALS 62
STEM CELL THERAPY FOR ALS 63
STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY 64
STEM CELL THERAPY AND BONE MARROW TRANSPLANTS 65
Stem Cell Therapy and … (Continued) 66
Chapter-7: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES 67
OSTEOBIOLOGICS 67
BONE GRAFTS 68
TABLE 10 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL 69
TABLE 11 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2014 70
TABLE 12 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2014 70
TABLE 13 BONE GRAFT MATERIALS 71
TABLE 13 (CONTINUED) 72
TABLE 14 SUBSTITUTE BONE GRAFTS 72
AUTOGRAFTS 73
BIOSEED GRAFTS 73
ALLOGRAFTS 74
Allografts (Continued) 75
DEMINERALIZED BONE MATRIX PRODUCTS 76
TABLE 15 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX 77
Accell 77
AlphaGRAFT 77
Allomatrix 78
Grafton DBM 78
DBX 78
DynaBlast and DynaGraft-D 78
Graftech 78
Grafton 78
Opteform 79
OrthoBlast II 79
Osteofil 79
Solo Cervical Allograft 80
XENOGRAFTS 80
THE MARKET FOR ALLOGRAFTS 80
TABLE 16 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2014 ($ MILLIONS) 80
FIGURE 1 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, 2007-2014 ($ MILLIONS) 81
CELL-BASED BONE GRAFT SUBSTITUTES 82
FACTOR-BASED BONE GRAFT SUBSTITUTES 82
Factor-based Bone Graft Substitutes (Continued) 83
BONE MORPHOGENIC PROTEINS 84
INDUCTOS 84
INFUSE BONE GRAFT 85
OP-1 IMPLANT 85
CERAMIC-BASED BONE GRAFT SUBSTITUTES 86
TYPES OF CERAMICS 86
Alpha-BSM 87
BioGran 87
Bio-Oss 88
BoneSource 88
Calcigen S 88
Collagraft Strip Bone Graft Matrix 88
Conduit TCP Granules 89
IsoTis Products 89
Mimix Bone Substitute Material 90
Norian SRS 90
OsteoGraf 90
Osteoset 90
OsteoStim Resorbable Bone Graft Substitute 91
PerioGlas 91
Pro Osteon Implant 91
Vitoss 91
POLYMER-BASED BONE GRAFT SUBSTITUTES 92
CORTOSS 92
HEALOS 93
IMMIX EXTENDERS AND IMMIX CB 94
THE MARKET FOR BONE GRAFT PRODUCTS 94
TABLE 17 WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2014 ($ MILLIONS) 94
FIGURE 2 WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, 2007-2014 ($ MILLIONS) 95
TABLE 18 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, THROUGH 2014 ($ MILLIONS) 96
FIGURE 3 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, 2007-2014 ($ MILLIONS) 96
REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS 96
BIOLOGIC/SYNTHETIC GRAFTS 97
CHRYSALIN 97
Chrysalin (Continued) 98
Chrysalin (Continued) 99
Chapter-8: REGENERATIVE APPLICATIONS FOR BONES AND JOINTS
MATERIALS FOR BONE TISSUE REPAIR 100
INHERENT REGENERATION OF BONE 100
OVERALL SIZE OF BONE GRAFT BUSINESS 101
BONE GRAFT SUBSTITUTES 102
ALLOGRAFT TISSUE 103
OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES 104
HYDROGELS AND REGENERATION 105
COMPOSITION AND METHOD FOR SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE AMPHIPHILES 106
CHONDROITINASE ABC I POLYNUCLEOTIDES 107
Abstract 107
TRANSDISCAL ADMINISTRATION OF CYCLINE COMPOUNDS 107
Abstract 107
COMPOSITION AND METHOD FOR PREPARING BIOCOMPATIBLE SURFACES 108
Abstract 108
SPINAL MOBILITY PRESERVATION APPARATUS HAVING AN EXPANDABLE MEMBRANE 108
Abstract 108
MAJOR DISEASES AND CONDITIONS AFFECTING BONES 109
OSTEOPOROSIS 110
Currently Available Products to Treat Osteoporosis 111
Bisphosphonates 111
Fosamax 112
Boniva 113
TABLE 19 DRUGS USED TO TREAT OSTEOPOROSIS 113
Hormones 114
Evista 114
Forteo 114
Forteo (Continued) 115
Forteo (Continued) 116
Miacalcin 117
STEROIDS AND OSTEOPOROSIS 117
Glucocorticoids 118
THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS. 118
TABLE 20 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2014 ($ MILLIONS) 119
FIGURE 4 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, 2007-2014 ($ MILLIONS) 119
PAGET’S DISEASE 119
DRUGS CURRENTLY AVAILABLE TO TREAT PAGET’S DISEASE 120
Actonel 120
Aredia 120
Skelid 121
Zometa 121
THE MARKET FOR PRODUCTS TO TREAT PAGET’S DISEASE 121
TABLE 21 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET’S DISEASE, THROUGH 2014 ($ MILLIONS) 121
FIGURE 5 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET’S DISEASE, 2007-2014 ($ MILLIONS) 122
INJURIES AND DEGENERATIVE CONDITIONS 122
HIP FRACTURES 123
TABLE 22 WORLDWIDE HIP FRACTURE VOLUMES, THROUGH 2014 124
TABLE 23 U.S. HIP FRACTURE VOLUMES, THROUGH 2014 124
TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS 124
TABLE 24 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2008 (%) 125
TABLE 25 U.S. RECONSTRUCTIVE DEVICE MARKET, 2008 (%) 125
MARKET LEADERS 125
JOINT-REPLACEMENT SURGERY 126
TABLE 26 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2014 126
TABLE 27 HISTORICAL RATES OF HIP REPLACEMEN IN SIX MAJOR STATES, 2001 126
TABLE 28 WORLDWIDE HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 127
FIGURE 6 WORLDWIDE HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 127
TABLE 29 U.S. HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 127
FIGURE 7 U.S. HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 128
KNEE REPLACEMENTS 128
TABLE 30 WORLDWIDE KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014 129
TABLE 31 U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014 129
TABLE 32 WORLDWIDE KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 129
FIGURE 8 WORLDWIDE KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 130
TABLE 33 U.S. KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 130
FIGURE 9 U.S. KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 131
TABLE 34 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, THROUGH 2014 ($ MILLIONS) 131
FIGURE 10 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, 2007-2014 ($ MILLIONS) 132
NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS 132
IMAGING AND REGENERATION 133
IMAGING AND REGENERATION (CONTINUED) 134
Chapter-9: ELECTRICAL BONE GROWTH STIMULATOR MARKET
OVERVIEW 135
SCIENTIFIC BASIS 136
ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING 137
MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS 138
BIOMET 138
ORTHOFIX 139
DJO, INC. 140
SMITH & NEPHEW 141
MARKET SIZE 141
TABLE 35 WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2014 ($ MILLIONS) 141
TABLE 36 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS) 142
Chapter-10: ORTHOPEDICS—FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT
SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS 143
TABLE 37 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008–2009 144
TABLE 37 (CONTINUED) 145
TABLE 37 (CONTINUED) 146
TABLE 37 (CONTINUED) 147
TABLE 37 (CONTINUED) 148
TABLE 37 (CONTINUED) 149
TABLE 37 (CONTINUED) 150
TABLE 37 (CONTINUED) 151
TABLE 37 (CONTINUED) 152
TABLE 37 (CONTINUED) 153
TABLE 37 (CONTINUED) 154
TABLE 37 (CONTINUED) 155
TABLE 37 (CONTINUED) 156
TABLE 37 (CONTINUED) 157
TABLE 37 (CONTINUED) 158
Chapter-11: MARKET FOR TISSUE ENGINEERING PRODUCTS
TISSUE ENGINEERING AND CELL THERAPY 159
RESEARCH INITIATIVES 160
RESEARCH INITIATIVES (CONTINUED) 161
RESEARCH INITIATIVES (CONTINUED) 162
Chapter-12: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY
OVERVIEW 163
INDICATIONS AND HISTORY 163
CHARACTERTISTICS AND MATERIALS 164
BARRIER MEMBRANES 164
NON-RESORBABLE 164
RESORBABLE 164
COLLAGEN RESORBABLE MEMBRANES 165
SYNTHETIC RESORBABLE MEMBRANES 165
Chapter-13: SKIN TECHNOLOGIES
SKIN TECHNOLOGIES (CONTINUED) 166
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS 167
TABLE 38 SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2014 ($ MILLIONS) 168
Chapter-14: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE
OVERVIEW 169
NEURODEGENERATIVE DISEASES 169
CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS 169
SPINAL CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL 170
SPINAL CORD INJURY, … (CONTINUED) 171
UNIVERSITY OF SOUTHERN CALIFORNIA (USC) 172
Chapter-15: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE
OVERVIEW 173
STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE 173
PARTICULAR R&D PRIORITIES 174
PARTICULAR R&D PRIORITIES (CONTINUED) 175
STEM CELLS AND BIOLOGICAL PACEMAKERS 176
HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS 176
OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART 177
OTHER CURRENT REGENERATIVE …(CONTINUED) 178
Chapter-16: REGENERATIVE MEDICINE AND DIABETES
BACKGROUND 179
POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE 179
POSSIBLE APPLICATIONS FOR … (CONTINUED) 180
Chapter-17: FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE
CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS 181
REGULATORY ENVIRONMENT 181
REGULATORY ENVIRONMENT (CONTINUED) 182
STATUS OF RESEARCH AND CLINICAL TRIALS 183
ANALYSIS OF CLINICAL TRIALS 184
TABLE 39 REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY 185
TABLE 40 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE STATUS, CONDITIONS, INTERVENTION, AND SPONSOR 185
TABLE 40 (CONTINUED) 186
TABLE 40 (CONTINUED) 187
TABLE 40 (CONTINUED) 188
TABLE 40 (CONTINUED) 189
TABLE 40 (CONTINUED) 190
TABLE 40 (CONTINUED) 191
TABLE 40 (CONTINUED) 192
TABLE 40 (CONTINUED) 193
TABLE 40 (CONTINUED) 194
TABLE 40 (CONTINUED) 195
TABLE 40 (CONTINUED) 196
TABLE 40 (CONTINUED) 197
TABLE 40 (CONTINUED) 198
TABLE 40 (CONTINUED) 199
TABLE 40 (CONTINUED) 200
TABLE 40 (CONTINUED) 201
TABLE 40 (CONTINUED) 202
TABLE 40 (CONTINUED) 203
TABLE 40 (CONTINUED) 204
TABLE 40 (CONTINUED) 205
TABLE 40 (CONTINUED) 206
TABLE 40 (CONTINUED) 207
TABLE 40 (CONTINUED) 208
TABLE 40 (CONTINUED) 209
Chapter-18: OVERSEAS ACTIVITIES
DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES 210
JAPAN 210
EUROPE 211
AUSTRALIA AND CHINA 212
Chapter-19: PATENT ANALYSIS
ANALYSIS 213
TISSUE ENGINEERING PATENTS 213
TABLE 41 MOST FREQUENTLY CITED PATENT ASSIGNEES IN TISSUE ENGINEERING FIELD 214
GEOGRAPHIC DISTRIBUTION 214
TABLE 42 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED, 1985–2009 (%) 215
RECENT PATENTS 215
DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS 215
Abstract 215
METHOD FOR PREPARING NOVEL TRANSCRIPTION FACTORS AND USE 216
Abstract 216
ENDODERM CELLS FROM HUMAN EMBRYONIC STEM CELLS 216
Abstract 216
GENES WITH ES CELL-SPECIFIC EXPRESSION 217
Abstract 217
MARKER SYSTEM FOR PREPARING AND CHARACTERIZING HIGH-QUALITY HUMAN EMBRYONIC STEM CELLS 217
Abstract 217
Chapter-20: COMPANY PROFILES
TABLE 43 PUBLICALLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF JULY 1, 2009 218
AASTROM BIOSCIENCES, INC. 219
ADVANCED BIOHEALING, INC. 219
ADVANCED CELL TECHNOLOGY, INC. 220
AESCULAP, INC. 221
ALDAGEN, INC. 221
ALPHATEC SPINE, INC. 222
ANGIOTECH PHARMACEUTICALS, INC. 222
ARTERIOCYTE MEDICAL SYSTEMS, INC. 223
ARTHREX, INC. 223
ARTHROCARE CORPORATION 223
BIOMET, INC. 224
BIOMIMETIC THERAPEUTICS, INC. 224
BIOTISSUE TECHNOLOGIES GMBH 224
CAPSTONE THERAPEUTICS 225
CENTERPULSE ORTHOPAEDICS, INC. 226
CERAPEDICS, INC. 226
CITAGENIX, INC. 226
CONMED CORPORATION 227
CROSSCART INC. 228
CRYOLIFE, INC. 229
CURIS 230
CYTORI THERAPEUTICS, INC. 231
DEPUY ORTHOPAEDICS, INC. (UNIT OF THE DEPUY COMPANIES) 231
DJO SURGICAL 232
ESBATECH AG 232
ETEX CORPORATION 233
EXACTECH, INC. 234
FATE THERAPEUTICS, INC. 234
GARNET BIOTHERAPEUTICS 234
GENZYME BIOSURGERY 235
GERON CORPORATION 236
INTEGRA LIFESCIENCES HOLDING CORP. 236
ISOTIS ORTHOBIOLOGICS, INC. (INTEGRA ORTHOBIOLOGICS) 237
INTERNATIONAL STEM CELL 237
INTERPORE CROSS INTERNATIONAL 238
ISTO TECHNOLOGIES, INC. 239
KENSEY NASH CORPORATION 240
LIFECELL (A SUBSIDIARY OF KINETIC CONCEPTS, INC.) 241
MCEWEN CENTRE FOR REGENERATIVE MEDICINE 241
MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE 242
MEDTRONIC, INC. 242
MESOBLAST, LIMITED 243
NATIONAL CENTER FOR REGENERATIVE MEDICINE 243
NATIONAL TISSUE ENGINEERING CENTER (NTEC) 244
NEURALSTEM 245
NOVABONE PRODUCTS, LLC 246
NOVARTIS CORPORATION 246
NOVOCELL, INC. 246
OPEXA THERAPEUTICS 246
ORGANOGENESIS INC. 247
ORTHOFIX INTERNATIONAL N.V. 248
ORTHOPEUTICS, L.P. 248
ORTHOVITA, INC. 249
OSIRIS THERAPEUTICS, INC. 249
OSTEOTECH, INC. 250
PFIZER, INC. 250
PLURISTEM THERAPEUTICS 250
REGEN BIOLOGICS, INC. 251
RENEURON 252
RTI BIOLOGICS, INC. 252
SCIL TECHNOLOGY GMBH 252
SMITH AND NEPHEW 253
STEMCELLS, INC. 253
STEMCOR SYSTEMS, INC. 254
STRAUMANN USA LLC 254
STRYKER CORP. 255
SYNTHES, INC. 255
TENGION 256
TEPHA 257
THERMOGENESIS CORP. 257
TIGENIX N.V. 258
UCB S.A. (HEADQUARTERS) 259
WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE 259
WRIGHT MEDICAL GROUP, INC. 260
ZIMMER HOLDINGS, INC. 261
OTHER ORGANIZATIONS INVOLVED IN REGENRERATIVE MEDICINE R&D 261
ACADEMIC INSTITUTIONS 261
U.S. GOVERNMENT 262
OTHER SOCIETIES AND ORGANIZATIONS 262
Chapter-21: GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS
GLOSSARY OF KEY TERMS 263
GLOSSARY OF KEY TERMS (CONTINUED) 264
GLOSSARY OF KEY TERMS (CONTINUED) 265
GLOSSARY OF KEY TERMS (CONTINUED) 266
GLOSSARY OF KEY TERMS (CONTINUED) 267
GLOSSARY OF KEY TERMS (CONTINUED) 268
GLOSSARY OF KEY TERMS (CONTINUED) 269
